DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Venbio Partners LLC
Venbio Partners LLC
venture manager, reported GAV $943M across 3 vehicles
Importance
36
elevated
Active deployment
29
moderate
Emerging
0
low
Completeness
69
high
Freshness
100
high
Research priority
13
low
Identity and regulatory footprint
- Headquarters
- San Francisco, CAadviserinfo.sec.gov
- Office address
- 1700 OWENS STREET, SUITE 595, San Francisco, CA, 94158-0008adviserinfo.sec.gov
- Business phone
- (415) 800-0800adviserinfo.sec.gov
- Website
- HTTP://WWW.VENBIO.COM
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 12, 2026
- Private funds reported
- 5 (5 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $1.8Badviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Owners on Schedule A
- Venbio Partners, L.P. (Owner), E; Venbio Partners Management Holdings GP, LLC (General Partner), F
- business phone
- (415) 800-0800adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
2 observed deals
Stated (the firm’s website)
- Sectors
- biotech, industrial
- Stages
- not stated or not yet read
- Geography
- seattle
- Check size
- not stated; DFX does not estimate checks from round sizes
- Self-described
- venture capital
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
Biotechnology 100%
lead rate n/afollow-on rate n/anew logos, 12 months 1
Funds and vehicles
3 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| venBio Global Strategic Fund V, L.P. | Fund | 2024 form d first sale | Early deployment | unknown | unknown | $505M | Jul 12, 2024 |
| Venbio Global Strategic Fund IV, L.P. | Fund | 2021 form d first sale | Mature | $550M Mar 13, 2024 | 147 | $550M of $550M | May 14, 2021 |
| Venbio Global Strategic Fund III, LP | Fund | 2018 form d first sale | Harvest | $393M Mar 13, 2024 | 103 | $386M of $386M | Mar 26, 2020 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
14 current, 0 departed
Parthiv Patel
AnalystAnalyst
Aaron Royston
Managing partnerManaging Partner
Corey Goodman
Managing partnerCo-founder and Managing Partner
Richard Gaster
Managing partnerManaging Partner
Robert Adelman
Managing partnerCo-founder and Emeritus Managing Partner
Aaron Royston
PartnerLimited Partner · since Apr 1, 2019
Corey S. Goodman
PartnerLimited Partner · since Jan 1, 2018
Richard Samuel Gaster
PartnerLimited Partner · since Jul 1, 2021
Robert Adelman
PartnerLimited Partner · since Jan 1, 2018
Yvonne Yamanaka
PartnerPartner
Antoinette Delhonte
Platform and operationsChief Financial Officer · since Aug 1, 2021
Daniel Teichmann
Platform and operationsController
David Pezeshki
Platform and operationsChief Operating Officer · since Jun 1, 2017
David Pezeshki
Platform and operationsChief Financial Officer
Investments on record
2 edges, 2 companies, 2 partner-attributed
| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| Caldera Therapeutics, Inc. | board seat | unknown · board | Aaron Royston (strongly supported) | unknown | unknown | Jan 21, 2026 | Inference SEC EDGAR Form D data sets (quarterly) |
| Marea Therapeutics, Inc. | board seat | unknown · board | Aaron Royston (strongly supported) | unknown | unknown | Jun 24, 2024 | Inference SEC EDGAR Form D data sets (quarterly) |
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
0 relationships from shared deals, counted for the whole firm
No co-investor relationship yet: these are derived only from rounds and portfolio listings the graph has seen both investors on.
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
8 dated events
- Mar 24, 2022Venbio Global Strategic Fund IV, L.P. first reported on Form ADV by Venbio Partners LLC (Venture Capital Fund), GAV $549,936,000Fund first reported on Form ADVFundsFactVenbio Global Strategic Fund IV, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Aug 1, 2021Antoinette Delhonte joined Schedule A of Venbio Partners LLC as Chief Financial Officer
- Apr 1, 2020Richard Samuel Gaster joined Schedule A of Venbio Partners LLC as Director
- Apr 1, 2019Aaron Royston joined Schedule A of Venbio Partners LLC as Limited Partner
- Mar 26, 2019Venbio Global Strategic Fund III, LP first reported on Form ADV by Venbio Partners LLC (Venture Capital Fund), GAV $119,191,919Fund first reported on Form ADVFundsFactVenbio Global Strategic Fund III, LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Sep 28, 2017Venbio Partners LLC first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Sep 28, 2017Venbio Global Strategic Fund II, L.P. first reported on Form ADV by Venbio Partners LLC (Venture Capital Fund), GAV $340,404,040Fund first reported on Form ADVFundsFactVenbio Global Strategic Fund II, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Sep 28, 2017Venbio Global Strategic Fund, L.P. first reported on Form ADV by Venbio Partners LLC (Venture Capital Fund), GAV $178,787,879Fund first reported on Form ADVFundsFactVenbio Global Strategic Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $943M across 3 vehicles
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $943M across 2 vehicles
Evidence
49 observations from 3 sources